
Publication summary: Woo K, et al. Int Wound J (2021)*

SmithNephew

Use of the IODOSORB^o Cadexomer Iodine Range[†] helped to reduce barriers to wound healing, significantly increasing the chance of complete healing compared with standard care in chronic wounds



Overview

- Systematic review and meta-analysis of comparative trials to determine the efficacy of the IODOSORB Range on chronic wounds versus standard care specific to the wound type
- Articles published up to 24 November 2020 were identified from PubMed (n=96), Embase (n=382) and Smith+Nephew records (n=2)
- In total, 13 studies were included in the final review
 - Studies included venous leg ulcers (VLUs; n=10), diabetic foot ulcers (DFUs; n=2) and pressure ulcers (PUs; n=1)
- Meta-analyses for outcome measures were only conducted where data was adequate for pooling

Results

- Pus/debris at 6–8 weeks was significantly reduced with the IODOSORB Range compared with standard care (3 studies; p<0.0001)
 - In individual studies, significant reductions were also consistently observed in wound healing barriers such as exudate, slough, biofilm and infection (p<0.05); however, meta-analyses were not performed
- Significantly greater reductions in wound area were observed after 8 weeks of treatment with the IODOSORB Range versus standard care (3 studies; mean difference, 2.35cm²; p=0.0219)
- Wounds were more than twice as likely to completely heal with the IODOSORB Range than with standard care (8 studies; p<0.0001; Figure)



Figure. Forest plot of complete wound healing with the IODOSORB Range and standard care in VLUs, DFUs and PUs $\,$

Conclusions

Use of the IODOSORB Range helped to reduce barriers to healing (exudate, slough, pus, debris, biofilm and infection), significantly reducing wound area and increasing the chance of healing chronic wounds (VLUs, DFUs and PUs) compared with standard care.

Citation

*Woo K, Dowsett C, Costa B, Ebohon S, Woodmansey EJ, Malone M. Efficacy of topical cadexomer iodine treatment in chronic wounds: Systematic review and meta-analysis of comparative clinical trials. *Int Wound J.* 2021;[Epub ahead of print]. Available at: International Wound Journal

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

†Includes IODOSORB 0.9% Cadexomer Iodine Ointment, IODOSORB 0.9% Cadexomer Iodine Gel, IODOSORB 0.9% Cadexomer Iodine Powder, IODOSORB 0.9% Cadexomer Iodine Dressing